Five Prime Therapeutics, Inc. FPRX Income Statement

Five prime therapeutics, inc. (FPRX)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Sep'12
Revenue:
Revenue from contracts with customers
-	-	15,695	18,482	-	49,868	54,170	56,221	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	34,306	-	385,770	384,948	382,034	379,801	22,519	0	0	-	0	-	-	-	-	-	-	-
Collaboration and license revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-
Collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	12,868	0	0	0
Operating expenses:
Research and development
100,866	114,063	122,859	140,598	144,553	156,352	154,290	152,336	160,700	150,908	147,386	128,543	108,976	94,072	85,879	86,709	77,842	70,197	61,812	46,895	45,458	43,173	38,679	37,069	33,781	32,785	31,218	0	0	0
General and administrative
42,730	42,749	42,956	39,582	39,703	39,671	40,571	40,413	39,994	40,002	40,045	39,517	38,260	35,831	33,911	29,978	26,468	22,631	17,997	16,144	14,572	13,632	12,706	11,953	11,315	10,427	9,642	0	0	0
Total operating expenses
143,596	156,812	165,815	180,180	184,256	196,023	194,861	192,749	200,694	190,910	187,431	168,060	147,236	129,903	119,790	116,687	104,310	92,828	79,809	63,039	60,030	56,805	51,385	49,022	45,096	43,212	40,860	0	0	0
Loss from operations
-125,655	-141,938	-150,120	-161,698	-161,527	-146,155	-135,806	-131,132	-138,835	-151,402	-152,879	-135,161	-112,930	-99,212	265,980	268,261	277,724	286,973	-58,704	-41,733	-40,058	-37,574	-33,014	-33,228	-30,734	-29,421	-27,992	0	0	0
Interest income
3,724	4,740	5,576	6,007	6,166	5,792	5,004	4,175	0	-	0	0	-	-	-	-	-	-	-	344	282	210	175	125	83	62	56	0	0	0
Other expense, net
-	-	-	0	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and other income, net
-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-
Other expense, net
-	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-76	42	182	487	0	0	0	-
Loss before income tax
-121,933	-137,202	-144,598	-155,773	-155,442	-140,447	-130,904	-126,942	-135,465	-148,518	-150,071	-132,506	-110,331	-96,745	267,956	269,702	278,636	287,457	0	0	0	-	-	-	-	-	-	-	-	-
Income tax provision
-	-	-	-	-	-	-	-	-	-	-	0	-	-31,048	17,419	23,722	30,993	37,810	0	0	0	-	-	-	-	-	-	-	-	-
Other income, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net loss
-121,933	-137,202	-144,598	-155,773	-155,442	-140,447	-130,905	-126,943	-137,169	-150,222	-141,117	-117,249	-86,100	-65,697	250,537	245,980	247,643	249,647	-58,307	-41,424	-39,816	-37,424	-32,915	-33,061	-30,469	-28,872	-27,413	0	0	0
Basic and diluted net loss per common share
-0.57	-0.88	-1.03	-0.99	-1.02	-1.14	-1.37	-0.99	-0.63	-1.05	-1.54	-1.58	-1.21	-0.74	-0.72	-0.49	-0.49	-	-0.93	-0.45	-0.44	-	-0.33	-0.46	-0.46	-	-2.74	-5.82	-5.73	-4.85
Weighted-average shares used to compute basic and diluted net loss per common share
35,263	35,181	34,996	34,909	34,794	34,707	34,482	34,401	32,314	28,157	28,020	27,946	27,657	27,406	27,139	26,924	26,351	-	25,825	25,690	25,072	-	21,521	21,465	18,841	-	2,637	1,250	1	1
Collaboration revenue [Member]
Total revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License revenue [Member]
Total revenue
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-